Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

19
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
19
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

137
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
137

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acetylated mitochondrial MDH2 regulates CTR2 transcription to induce cuproptosis during Escherichia coli infection.

Nature communications·2026
Same author

Surface modification of chitin nanocrystals with hydroxyapatite deposition and polymer grafting for poly(lactic acid)-based osteogenic biomaterials.

International journal of biological macromolecules·2026
Same author

Intestinal epithelial Syndecan-1 maintains mucosal homeostasis in inflammatory bowel disease by enhancing <i>Faecalibacterium prausnitzii</i> biofilm formation.

Gut microbes·2026
Same author

Efficacy and safety of fecal microbiota transplantation in reducing recurrence of colorectal adenomas after endoscopic resection: study protocol for a multicenter, open-label, randomized, no-treatment-controlled trial.

Trials·2026
Same author

Advance Microbiota Transplantation: A Novel Addition-Subtraction Paradigm for Optimising Faecal Microbiota Transplantation.

Microbial biotechnology·2026
Same author

A Boruta-SMOTE Integrated Approach for Rapid Donkey Breed Classification Using SNP Data: Addressing High-Dimensionality and Small Sample Challenges.

Biochemical genetics·2026

Related Experiment Video

Updated: May 17, 2025

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.3K

Dexmedetomidine for modified electroconvulsive therapy: a dose-optimized treatment study.

Jun Shen1, Min Zhou1, Guangliang Zhu1

  • 1Department of Anesthesiology, Affiliated Hospital of West Anhui Health Vocational College, Lu'an, Anhui, 237000, People's Republic of China.

European Journal of Medical Research
|April 4, 2025
PubMed
Summary

The optimal dexmedetomidine dose for modified electroconvulsive therapy (MECT) is 0.4 mcg/kg. This dose balances hemodynamic stability and rapid recovery while reducing propofol requirements.

Keywords:
AnesthesiaDexmedetomidineModified electroconvulsive therapyOptimal dosePreconditioning

More Related Videos

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.9K
A Guide to In vivo Single-unit Recording from Optogenetically Identified Cortical Inhibitory Interneurons
10:32

A Guide to In vivo Single-unit Recording from Optogenetically Identified Cortical Inhibitory Interneurons

Published on: November 7, 2014

19.1K

Related Experiment Videos

Last Updated: May 17, 2025

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy
04:51

Pupillary Response as Assessment of Effective Seizure Induction by Electroconvulsive Therapy

Published on: April 11, 2019

9.3K
Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins
09:07

Electroconvulsive Seizures in Rats and Fractionation of Their Hippocampi to Examine Seizure-induced Changes in Postsynaptic Density Proteins

Published on: August 15, 2017

11.9K
A Guide to In vivo Single-unit Recording from Optogenetically Identified Cortical Inhibitory Interneurons
10:32

A Guide to In vivo Single-unit Recording from Optogenetically Identified Cortical Inhibitory Interneurons

Published on: November 7, 2014

19.1K

Area of Science:

  • Anesthesiology
  • Pharmacology
  • Neuroscience

Background:

  • Modified electroconvulsive therapy (MECT) requires careful anesthetic management.
  • Hemodynamic stability and quality of recovery are critical during MECT.

Purpose of the Study:

  • To identify the optimal dexmedetomidine dosage for enhancing hemodynamic stability and recovery during MECT.
  • To evaluate the dose-dependent effects of dexmedetomidine on MECT anesthesia.

Main Methods:

  • A randomized trial involving 252 patients undergoing MECT.
  • Patients were assigned to six groups: placebo and five dexmedetomidine doses (0.2-1.0 mcg/kg).
  • Hemodynamic parameters, seizure duration, propofol use, and recovery times were analyzed.

Main Results:

  • Dexmedetomidine doses of 0.4 mcg/kg and higher significantly reduced heart rate and mean arterial pressure.
  • Higher doses (≥0.4 mcg/kg) led to a dose-dependent decrease in propofol requirements.
  • The 0.4 mcg/kg dose (D2 group) provided optimal hemodynamic control without significantly delaying recovery.

Conclusions:

  • Pretreatment with dexmedetomidine at 0.4 mcg/kg is recommended for MECT anesthesia.
  • This dosage optimizes the balance between hemodynamic stability, reduced propofol needs, and prompt recovery.
  • Dexmedetomidine at 0.4 mcg/kg represents a safe and effective anesthetic adjunct for MECT.